Mitsubishi Tanabe Pharma Corporation - Product Pipeline Review - 2016

Published: Sep, 2016 | Pages: 111 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Mitsubishi Tanabe Pharma Corporation - Product Pipeline Review - 2016

Summary

Global Markets Direct's, 'Mitsubishi Tanabe Pharma Corporation - Product Pipeline Review - 2016', provides an overview of the Mitsubishi Tanabe Pharma Corporation's pharmaceutical research and development focus. 

The report provides comprehensive information on the therapeutics under development by Mitsubishi Tanabe Pharma Corporation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Mitsubishi Tanabe Pharma Corporation
- The report provides overview of Mitsubishi Tanabe Pharma Corporation including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses Mitsubishi Tanabe Pharma Corporation's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features Mitsubishi Tanabe Pharma Corporation's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons To Buy

- Evaluate Mitsubishi Tanabe Pharma Corporation's strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Mitsubishi Tanabe Pharma Corporation
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Mitsubishi Tanabe Pharma Corporation's pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 7
Mitsubishi Tanabe Pharma Corporation Snapshot 8
Mitsubishi Tanabe Pharma Corporation Overview 8
Key Facts 8
Mitsubishi Tanabe Pharma Corporation - Research and Development Overview 9
Key Therapeutic Areas 9
Mitsubishi Tanabe Pharma Corporation - Pipeline Review 13
Pipeline Products by Stage of Development 13
Pipeline Products - Monotherapy 14
Pipeline Products - Combination Treatment Modalities 15
Pipeline Products - Partnered Products 16
Partnered Products/Combination Treatment Modalities 17
Pipeline Products - Out-Licensed Products 18
Out-Licensed Products/Combination Treatment Modalities 19
Mitsubishi Tanabe Pharma Corporation - Pipeline Products Glance 20
Mitsubishi Tanabe Pharma Corporation - Late Stage Pipeline Products 20
Pre-Registration Products/Combination Treatment Modalities 20
Phase III Products/Combination Treatment Modalities 21
Mitsubishi Tanabe Pharma Corporation - Clinical Stage Pipeline Products 22
Phase II Products/Combination Treatment Modalities 22
Phase I Products/Combination Treatment Modalities 23
Mitsubishi Tanabe Pharma Corporation - Early Stage Pipeline Products 24
IND/CTA Filed Products/Combination Treatment Modalities 24
Preclinical Products/Combination Treatment Modalities 25
Discovery Products/Combination Treatment Modalities 26
Mitsubishi Tanabe Pharma Corporation - Drug Profiles 27
(canagliflozin + teneligliptin) - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
amiselimod hydrochloride - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
avanafil - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
bepotastine besylate - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
canagliflozin - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
cariprazine - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
edaravone - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
fingolimod hydrochloride - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
GB-1057 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
infliximab - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
masilukast - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
MIN-117 - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
Monoclonal Antibodies for Cancer - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
Monoclonal Antibodies for Inflammatory Disorders - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
Monoclonal Antibodies for Undisclosed Indication - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
MP-124 - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
MP-157 - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
MT-0814 - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
MT-210 - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
MT-3995 - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
MT-4580 - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
MT-7117 - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
MT-8554 - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
NU-300 - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
Small Molecule to Inhibit PDE5 for Erectile Dysfunction - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
Small Molecule to Inhibit S-Adenosyl-L-Homocysteine Hydrolase for Undisclosed Indication - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
Small Molecules to Block Sodium and hERG Channel for Ischemic Stroke - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
Small Molecules to Inhibit DPP-IV for Hyperglycemia - Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
Small Molecules to Inhibit GSK-3 Beta for Neurodegenerative Diseases - Drug Profile 78
Product Description 78
Mechanism Of Action 78
R&D Progress 78
T-6932 - Drug Profile 79
Product Description 79
Mechanism Of Action 79
R&D Progress 79
TA-3404 - Drug Profile 80
Product Description 80
Mechanism Of Action 80
R&D Progress 80
teneligliptin - Drug Profile 81
Product Description 81
Mechanism Of Action 81
R&D Progress 81
valbenazine tosylate - Drug Profile 83
Product Description 83
Mechanism Of Action 83
R&D Progress 83
Y-320 - Drug Profile 88
Product Description 88
Mechanism Of Action 88
R&D Progress 88
Mitsubishi Tanabe Pharma Corporation - Pipeline Analysis 89
Mitsubishi Tanabe Pharma Corporation - Pipeline Products by Target 89
Mitsubishi Tanabe Pharma Corporation - Pipeline Products by Route of Administration 92
Mitsubishi Tanabe Pharma Corporation - Pipeline Products by Molecule Type 93
Mitsubishi Tanabe Pharma Corporation - Pipeline Products by Mechanism of Action 94
Mitsubishi Tanabe Pharma Corporation - Dormant Projects 97
Mitsubishi Tanabe Pharma Corporation - Discontinued Pipeline Products 99
Discontinued Pipeline Product Profiles 101
AMG-899 101
AV-412 101
caldaret 101
carmoterol 101
coleneuramide 101
colestilan chloride 101
ecabet 101
edaravone 102
encenicline hydrochloride 102
fingolimod hydrochloride 102
immune globulin (human) 102
marimastat 102
masilukast 103
MP-136 103
MP-435 103
MT-7716 103
netoglitazone 103
sofigatran 103
TA-5493 103
TA-5538 103
TA-6666 103
TAK-128 103
telaprevir 104
Y-700 104
Mitsubishi Tanabe Pharma Corporation - Company Statement 105
Mitsubishi Tanabe Pharma Corporation - Locations And Subsidiaries 106
Head Office 106
Other Locations & Subsidiaries 106

Appendix 110
Methodology 110
Coverage 110
Secondary Research 110
Primary Research 110
Expert Panel Validation 110
Contact Us 110
Disclaimer 111

List of Tables

Mitsubishi Tanabe Pharma Corporation, Key Facts 8
Mitsubishi Tanabe Pharma Corporation - Pipeline by Indication, 2016 11
Mitsubishi Tanabe Pharma Corporation - Pipeline by Stage of Development, 2016 13
Mitsubishi Tanabe Pharma Corporation - Monotherapy Products in Pipeline, 2016 14
Mitsubishi Tanabe Pharma Corporation - Combination Treatment Modalities in Pipeline, 2016 15
Mitsubishi Tanabe Pharma Corporation - Partnered Products in Pipeline, 2016 16
Mitsubishi Tanabe Pharma Corporation - Partnered Products/ Combination Treatment Modalities, 2016 17
Mitsubishi Tanabe Pharma Corporation - Out-Licensed Products in Pipeline, 2016 18
Mitsubishi Tanabe Pharma Corporation - Out-Licensed Products/ Combination Treatment Modalities, 2016 19
Mitsubishi Tanabe Pharma Corporation - Pre-Registration, 2016 20
Mitsubishi Tanabe Pharma Corporation - Phase III, 2016 21
Mitsubishi Tanabe Pharma Corporation - Phase II, 2016 22
Mitsubishi Tanabe Pharma Corporation - Phase I, 2016 23
Mitsubishi Tanabe Pharma Corporation - IND/CTA Filed, 2016 24
Mitsubishi Tanabe Pharma Corporation - Preclinical, 2016 25
Mitsubishi Tanabe Pharma Corporation - Discovery, 2016 26
Mitsubishi Tanabe Pharma Corporation - Pipeline by Target, 2016 90
Mitsubishi Tanabe Pharma Corporation - Pipeline by Route of Administration, 2016 92
Mitsubishi Tanabe Pharma Corporation - Pipeline by Molecule Type, 2016 93
Mitsubishi Tanabe Pharma Corporation - Pipeline Products by Mechanism of Action, 2016 95
Mitsubishi Tanabe Pharma Corporation - Dormant Developmental Projects,2016 97
Mitsubishi Tanabe Pharma Corporation - Discontinued Pipeline Products, 2016 99
Mitsubishi Tanabe Pharma Corporation, Other Locations 106
Mitsubishi Tanabe Pharma Corporation, Subsidiaries 107